ClinicalTrials.Veeva

Menu

Treatment Outcomes in Patient With Nontuberculous Mycobacterial Disease

University of Illinois logo

University of Illinois

Status

Terminated

Conditions

Nontuberculous Mycobacterial Disease
Atypical Mycobacterium Infections

Study type

Observational

Funder types

Other

Identifiers

NCT01680822
2012-0662
UIC (Other Identifier)

Details and patient eligibility

About

Little is known about the disease caused by the nontuberculous or environmental mycobacteria (NTM) and only limited data are available showing treatment outcome. This project will study the patients with nontuberculous mycobacterial (NTM) diseases in the University of Illinois Hospital & Health Sciences System (UIMC). The aim of study is finding treatment outcome and risk factors that are associated with treatment failure in NTM patients. This is a retrospective, observational study for collecting data on patients with NTM in UIMC. The study initially involves populating the study of NTM patients seen at UIMC during the study period. This will add our knowledge about current treatment outcome of patients with NTM diseases and will be of interest to physicians, and public health authorities.

Full description

The study focuses on collecting all mycobacterial data, clinical assessment and clinical outcomes of patients. Data collection includes demographic characteristics, medical history, clinical procedures relative to the treatment of NTM, respiratory symptoms and signs, pulmonary function tests if applicable, imaging parameters, diagnostic tests, mycobacterial smear, culture, or possible susceptibility, therapies and outcome. The study will be updated with clinical outcomes (e.g., hospitalization, surgery relative NTM, and death) during study period. The data will be collected from 1/1/2001 to 12/30/ 2011.

The confirmed NTM patient will be defined with ATS guideline for NTM as:

Clinical: Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or an HRCT scan that shows multifocal bronchiectasis with multiple small nodules and 2. appropriate exclusion of other diagnoses.

Microbiologic: Positive culture results from at least two separate expectorated sputum samples. (If the results from the initial sputum samples are nondiagnostic, we will consider repeat sputum AFB smears and cultures.) Or positive culture results from at least one bronchial wash or lavage. Or transbronchial or other lung biopsy with mycobacterial histopathologic features (granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathologic features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that are culture positive for NTM.

OBJECTIVES

  1. To determine prevalence of culture-confirmed NTM infection in the UIMC in a ten- year period
  2. To determine the prevalence of NTM disease based on ATS case definition the UIMC in a ten- year period
  3. To determine treatment outcome of NTM disease in the UIMC in a ten- year period
  4. To find the risk factors associated with treatment failure of patients with NTM diseases

Enrollment

150 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged 18 year or older with at least one culture-confirmed NTM.

Exclusion criteria

  • All patients aged younger than 18 years old.
  • No individuals are excluded from study based on, race, ethnicity, gender, or HIV status.

Trial design

150 participants in 1 patient group

NTM patient
Description:
confirmed NTM patient

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems